Comparative Pharmacology
Head-to-head clinical analysis: MONJUVI versus PRALATREXATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONJUVI versus PRALATREXATE.
MONJUVI vs PRALATREXATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MONJUVI (tafasitamab-cxix) is a humanized Fc-engineered CD19-directed cytolytic monoclonal antibody. It binds to CD19 antigen on the surface of pre-B and mature B lymphocytes, and upon binding, facilitates antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
Folate analogue metabolic inhibitor that competitively inhibits dihydrofolate reductase (DHFR), disrupting DNA synthesis and cell proliferation.
3 mg/kg intravenously over 60 minutes every 2 weeks until disease progression or unacceptable toxicity.
30 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Clinical Note
moderatePralatrexate + Digoxin
"Pralatrexate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePralatrexate + Digitoxin
"Pralatrexate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePralatrexate + Deslanoside
"Pralatrexate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePralatrexate + Acetyldigitoxin
"Pralatrexate may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: approximately 17 days (range 11-27 days). This supports a dosing interval of every 2 weeks, as steady state is reached by approximately 70 days.
Terminal elimination half-life is approximately 12–19 hours in patients with normal renal function, supporting a weekly dosing interval.
Monjuvi (tafasitamab-cxix) is a monoclonal antibody primarily catabolized into small peptides and amino acids. No specific data on renal or biliary excretion; minimal intact drug excreted in urine or feces. Expected to undergo general protein degradation.
Renal excretion accounts for approximately 70-80% of the administered dose as unchanged drug; biliary/fecal elimination is minimal (<10%).
Category C
Category C
Antineoplastic
Antineoplastic